These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8477411)

  • 21. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
    van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
    Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
    van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
    Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apomorphine in the diagnosis and treatment of parkinsonian tremor.
    Hughes AJ; Lees AJ; Stern GM
    Clin Neuropharmacol; 1990 Aug; 13(4):312-7. PubMed ID: 2208183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of sublingual apomorphine in Parkinson's disease.
    Durif F; Deffond D; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1990 Dec; 53(12):1105. PubMed ID: 2292708
    [No Abstract]   [Full Text] [Related]  

  • 25. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal apomorphine in parkinsonian on-off fluctuations.
    van Laar T; Jansen EN; Essink AW; Neef C
    Arch Neurol; 1992 May; 49(5):482-4. PubMed ID: 1580809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease.
    Ingram WM; Priston MJ; Sewell GJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):1-7. PubMed ID: 16364696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
    van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
    Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
    Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
    Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
    Rascol O; Azulay JP; Blin O; Bonnet AM; Brefel-Courbon C; Césaro P; Damier P; Debilly B; Durif F; Galitzky M; Grouin JM; Pennaforte S; Villafane G; Yaici S; Agid Y
    Mov Disord; 2010 Feb; 25(3):368-76. PubMed ID: 20063435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
    Grandas F; Obeso JA
    Clin Neuropharmacol; 1989 Feb; 12(1):14-22. PubMed ID: 2713864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses.
    Hofstee DJ; Neef C; van Laar T; Jansen EN
    Clin Neuropharmacol; 1994 Feb; 17(1):45-52. PubMed ID: 8149359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease.
    Grosset KA; Malek N; Morgan F; Grosset DG
    Eur J Neurol; 2013 Nov; 20(11):1445-50. PubMed ID: 23350812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual apomorphine in the treatment of Parkinson's disease.
    Kassubek J; Jost WH; Schwarz J
    J Neural Transm (Vienna); 2024 Oct; 131(10):1209-1216. PubMed ID: 38743091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.